Every year, IHBI, bluebox and QUT’s Division of Research and Commercialisation sponsor three early- to mid-career researchers to attend the Biotechnology Industry Organisation (BIO) conference in the USA. This year, Dr Melissa Fernandez, Dr Roland Steck and Dr Eliza Whiteside have been selected as the 2013 BIO Fellows. Today we will meet Dr Eliza Whiteside.
Dr Eliza Whiteside is a Queensland University of Technology (QUT) lecturer in biotechnology and an early career researcher at the Institute of Health and Biomedical Innovation in the field of medical biotechnology. Although trained as a basic scientist with a strong molecular and cell biology skill set, Eliza’s current research interests and growing expertise is in the area of translatable, patient-focused research. Eliza’s own personal battle with breast cancer and her volunteer role with the National Breast Cancer Foundation in Australia have inspired her to investigate novel genetic and proteomic biomarkers as indicators of breast cancer risk and recurrence, as well as ‘wellness’ in breast cancer sufferers. Eliza and her research group are primarily focused on the role of glycoprotein hormones and their receptors and employ loss of function and over-expression models using cell and molecular-based technologies to investigate tumourigenesis and cancer progression. Her group’s research is also investigating the use of novel and established pharmaceuticals, nutraceuticals, physical activity and sleep to ameliorate the side effects of common breast cancer treatments.
BIO is the largest biotechnology conference in the world, with approximately 16,500 attendees expected to attend this year’s event in Chicago. Along with a feature-packed conference program, BIO also offers a one-on-one BIO Business Forum and an exhibition hall with over 1,600 companies showcasing their latest products and technologies. BIO covers the complete spectrum of life sciences areas and biotechnology applications. From drug discovery to biomanufacturing, genomics to biofuels, cell therapy to nanotechnology – BIO has it covered.